Researchers are going to provide clues during this week with regard to Eli Lilly & Co’s bet on one experimental drug that was meant to work on Alzheimer’s disease which may or not may off for patients as well as the company’s bottom line.
Researchers are going to show results from one clinical trial for this drug, solanezumab, in Washington at Alzheimer’s Association International Conference. The outcome here is going to signal whether this drug is going to be able to overcome the negative studies of the past and be the first treatment to be marketed to help slow the progression of Alzheimer’s. The current treatment for this disease can certainly alleviate symptoms but it does nothing as far as slowing the progress of the disease is concerned.
This brain disorder, known to cause dementia affects more than 5 million Americans. It has been quite a tough disease to try and crack though since scientists still have no idea as to what it is caused by. Companies have scrapped a number of drugs in the past which showed promise before eventually failing during clinical trials.
In spite of these setbacks, the industry still hunts for a better treatment simply because of limitations of the current options. There is a huge market opportunity waiting for any drug that can halt or at least slow down its progression. The drug is estimated to generate sales worth more than $ 3 billion throughout the world if it gets approved by regulators.
The anticipation for this data is one of the reasons why Lilly’s shares have risen by 26% till now and hit a 10 year high recently as well. Positive results will definitely bolster the outlook for this company’s sales & earnings as it attempts to forget about patent expirations on earlier blockbusters.
The results are due within a week and are simply extensions of a couple of studies reported during 2012. Lilly provided the drug to a few patients who had originally received it as well and also allowed patients with placebo initially to change to solanezumab.
The data is going to be presented on Wednesday.
Benzamin H
Latest posts by Benzamin H (see all)
- Abby-Hickling Marriage: One way to please a four-year-old leukemia patient - July 19, 2015
- You should be careful: Fecal bacteria might have flooded 10 percent of the beaches in the United States - July 19, 2015
- Dallas Police: 2 year-old toddler dies after being left in hot car as Parents took an afternoon nap - July 19, 2015
